Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.

Abstract

Therapeutics of metastatic or triple-negative breast cancer are still challenging in clinical. Herein we demonstrated the design and optimization of a series of hybrid of 2,4-diaminopyrimidine and arylthiazole derivatives for their anti-proliferative properties against two breast cancer cell lines (MCF-7 as human breast cancer and MDA-MB-231 as triple-negative breast cancer). More importantly, some of those compounds with potent antiproliferative activities also indicated excellent inhibitory activities against MDA-MB-231 cell migration. These results suggested that the new series of hybridation of aryl-thiazoles and aminopyrimidines could be identified and developed as novel highly potential anticancer agents against the triple-negative breast cancer as well as metastatic one in the future.

• Authors: Wenbo Zhou, Anling Huang, Yong Zhang, Qingxiang Lin, Weikai Guo, Zihua You, Zhengfang Yi, Mingyao Liu, Yihua Chen
• Journal: European journal of medicinal chemistry (Eur J Med Chem) Vol. 96 Pg. 269-80 ( 2015) ISSN: 1768-3254 [Electronic] France
• PMID: 25899332 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Chemical References

• Antineoplastic Agents
• Pyrimidines
• Thiazoles
• 2,4-diaminopyrimidine

Topics

• Antineoplastic Agents (chemical synthesis, chemistry, pharmacology)
• Cell Cycle (drug effects)
• Cell Movement (drug effects)
• Cell Proliferation (drug effects)
• Dose-Response Relationship, Drug
• Drug Design
• Drug Screening Assays, Antitumor
• Humans
• MCF-7 Cells
• Molecular Structure
• Pyrimidines (chemical synthesis, chemistry, pharmacology)
• Structure-Activity Relationship
• Thiazoles (chemical synthesis, chemistry, pharmacology)
• Tumor Cells, Cultured